Displaying 1 - 12 of 12
| Active Ingredient | ANTIEMETICS |
| Therapeutic Class | ANTIEMETICS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | DIMENHYDRINATE |
| Therapeutic Class | ANTIEMETICS |
| Indications |
Prevention and treatment of nausea, vomiting and the vertigo of motion sickness. |
| Caution | Drowsiness, dry mouth. Patients should be warned against driving or performing other tasks requiring alertness. c.f. prescribing in liver and renal disease p. 13; 28. |
| Dose Range |
Adult: 50-100mg 2-3 times daily to a maximum of 300mg or 6 tabs. in 24 hours. Supp: 50-100mg 2-3 times daily . i.v: 50mg as needed. Pediatric: 2-6 years: 12.5mg;-25mg every 6-8 hours. 6- 12 y ears: 25-50mg 2-3 times daily . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | DRONABINOL |
| Therapeutic Class | ANTIEMETICS |
| Indications | Synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is a More ... |
| Caution | The most frequent adverse effects of dronabinol include abdominal pain, nausea and vomiting, dizziness, euphoria, paranoid reactions, and somnolence. Seizures and seizure-like activity have been repor More ... |
| Dose Range | Nausea and vomiting associated with chemotherapy. Dose is based on body surface area and is determined by the physician. The usual initial oral dose of dronabinol is 5 mg/m2 given 1 to 3 hours before the first dose of the antineoplastic drug with subsequ |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | GRANISETRON |
| Therapeutic Class | ANTIEMETICS |
| Indications |
Management of nausea and vomiting induced by cytotoxic chemotherapy andradiotherapy, treatment of postoperative nausea and vomiting. |
| Caution | Constipation; diarrhoea; headache; insomnia. |
| Dose Range |
Adult: 1 mg, dose to be diluted to 5 mL and given over 30 seconds; maximum 3 mg p er day . |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | FAMOTIDINE |
| Therapeutic Class | HISTAMINE RECEPTOR ANTAGONIST |
| Indications | Gastric, duodenal ulcers, GERD and Zollinger Ellison Syndrome. |
| Caution | Headaches, dizziness, constipation. C.f. prescribing in renal disease p. 29. |
| Dose Range | Adult: Gastric/Duodenal Ulcer:40mg at night for 4-8 weeks; maintenance 20mg at night. GERD: 20 mg twice daily for 6 to 12 weeks, or up to 40 mg twice daily if there is oesophageal erosion or ulceration.. Inj:20mg over 2 mins.every 12 hours. Pediatric |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | RANITIDINE |
| Therapeutic Class | HISTAMINE RECEPTOR ANTAGONIST |
| Indications |
Treatment of peptic ulcer disease, GERD and Zollinger Ellison Syndrome. |
| Caution |
See Famotidine. c.f. prescribing in liver and renal disease p. 17; 36. |
| Dose Range |
Adult and children 12 years and over: 150mg twice daily with breakfast or at night; or 300mg as a single dose at night. Maintenance: 150mg at night. i.m/i.v 50mg given slowly over 2 minutes repeated every 6-8 hours. Pediatric 3-12 yrs: |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | SUCRALFATE |
| Therapeutic Class | GI PROTECTANTS |
| Indications | Gastric and duodenal ulcers, chronic gastritis. |
| Caution | Constipation, gastric discomfort, diarrhoea. c.f. prescribing in renal disease p. 37. |
| Dose Range | Adult and children 15 years and over: 1g every 6 hours (1 hour before meals and at bedtime) or 2g every 12 hours (on rising and at bedtime). Pediatric 1 month-2 yrs: 0.25g 4-6 times daily ; 2-12 yrs: 0.5g 4-6 times daily ; 12-15 yrs: 1g 4-6 times dai |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ESOMEPRAZOLE |
| Therapeutic Class | PROTON PUMP INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | LANSOPRAZOLE |
| Therapeutic Class | PROTON PUMP INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | OMEPRAZOLE |
| Therapeutic Class | PROTON PUMP INHIBITORS |
| Indications | Duodenal and gastric ulcers. Gastroesophageal reflux disease. |
| Caution |
Constipation, diarrhea, headache, nausea, rash. Capsule is to be swallowed whole. c.f. prescribing in liver disease p. 16. |
| Dose Range | Peptic ulcer: 20 - 40 mg daily depending on severity ; 4 weeks for duodenal ulcer and 8 weeks for gastric ulcer; maintenance: 20 mg once daily .GERD: 20mg once daily for 4 weeks, followed by a further 4 - 8 weeks if not fully healed. Take before break |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | PANTOPRAZOLE |
| Therapeutic Class | PROTON PUMP INHIBITORS |
| Indications | Short term treatment of GERD (7-10 day s). |
| Caution | Diarrhea, nausea, headache. Safety and efficacy not established in children. |
| Dose Range | i.v: 40mg once daily for 7-10 day . See protocol pg. xiii section 7 and 8. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | RABEPRAZOLE |
| Therapeutic Class | PROTON PUMP INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |